Intellia Therapeutics, Inc.
(NASDAQ : NTLA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
TSROTESARO, Inc.
-1.07%73.6914.4%$580.10m
AMGNAmgen Inc.
-2.76%192.071.2%$565.07m
GILDGilead Sciences, Inc.
-2.64%65.570.9%$530.36m
CELGCelgene Corporation
-2.21%68.201.2%$520.26m
BIIBBiogen Inc.
-1.75%314.551.3%$359.40m
ILMNIllumina, Inc.
-2.44%326.463.5%$350.15m
REGNRegeneron Pharmaceuticals, Inc.
0.70%381.172.6%$273.12m
VRTXVertex Pharmaceuticals Incorporated
-1.94%170.061.9%$226.47m
AAgilent Technologies, Inc.
-2.49%69.371.5%$225.54m
ALXNAlexion Pharmaceuticals, Inc.
-2.67%109.432.0%$146.61m
INCYIncyte Corporation
-1.55%66.252.5%$97.76m
EXASExact Sciences Corporation
0.68%68.3125.3%$93.39m
SRPTSarepta Therapeutics, Inc.
-2.05%119.5215.4%$90.77m
NKTRNektar Therapeutics
-3.92%36.515.5%$84.08m
SGENSeattle Genetics, Inc.
-0.85%60.486.6%$81.91m

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.